The medical landscape is evolving, particularly in the field of gene therapy, which offers new hope for those affected by rare diseases. A significant advancement has taken place at Medcare Women & Children Hospital, where a groundbreaking intrathecal gene therapy for Spinal Muscular Atrophy (SMA) was successfully administered to a three-year-old patient from Turkey. This achievement marks Medcare as one of the first private healthcare institutions worldwide to provide this innovative treatment to an international patient, effectively overcoming previous constraints related to patient age and weight.
Understanding Spinal Muscular Atrophy
SMA is a rare neuromuscular disorder characterized by the progressive degeneration of motor neurons, leading to muscle weakness and respiratory complications. The introduction of a one-time gene therapy offers a transformative approach for patients, potentially altering the trajectory of their condition. This therapy, developed by Novartis, received approval from both the US Food and Drug Administration (FDA) and UAE authorities last month, with its initial application occurring just two days ago at Sheikh Khalifa Medical City in Abu Dhabi.
A New Era of Treatment Options
The life of young Hulus, who previously relied on intensive physiotherapy and hydrotherapy, has been significantly impacted by this new treatment. Hulus’ father, Mustafa, expressed his optimism, stating that the therapy has revitalized their hopes for a better quality of life and increased independence for his son. This narrative resonates with many families who have faced the daunting challenges associated with SMA.
Medcare’s Commitment to Rare Diseases
Dr. Shanila Laiju, the Group CEO of Medcare Hospitals & Medical Centres, emphasized the importance of this moment for SMA care in the region. According to her, families whose children were once deemed ineligible for gene therapy now have access to a revolutionary treatment capable of significantly improving clinical outcomes. This development underscores Medcare’s dedication to addressing the needs of children with rare diseases through specialized expertise and advanced medical infrastructure.
Impact on Medical Tourism
Since 2020, Medcare has treated over 180 children with SMA, welcoming patients from diverse regions including Iran, Turkey, Nepal, Romania, Russia, Kazakhstan, Kyrgyzstan, Ukraine, Belarus, Lebanon, India, and Ethiopia. This initiative not only highlights Dubai’s role as a strategic global hub for medical tourism but also positions it as a leader in pediatric genetic care.
A Multidisciplinary Approach
Medcare’s delivery of SMA care is founded on a multidisciplinary model that integrates various medical specialties such as neurology, pulmonology, orthopedics, rehabilitation, genetic counseling, and long-term follow-up for international patients. This comprehensive approach ensures that each child receives well-rounded care tailored to their unique needs.
Expanding Patient Eligibility
Consultant Pediatric Neurologist Dr. Vivek Mundada noted that the new therapy allows older and heavier patients to benefit from this transformative treatment. This shift represents a significant advancement in SMA care, moving beyond merely ensuring infant survival to focusing on preserving mobility, independence, and respiratory function in older patients.
Conclusion
The introduction of intrathecal gene therapy at Medcare signifies a monumental step forward in the treatment of Spinal Muscular Atrophy. With its commitment to innovative healthcare solutions and a patient-centered approach, Medcare is not only enhancing the lives of patients but also shaping the future of medical care for rare diseases. As this field continues to evolve, the hope for improved outcomes will resonate with families across the globe.
- Key Takeaways:
- Medcare successfully administered intrathecal gene therapy for SMA to an international patient.
- SMA is a progressive neuromuscular disorder with new treatment options available.
- A multidisciplinary approach enhances the quality of care for affected children.
- Dubai is positioning itself as a global hub for medical tourism and pediatric genetic care.
- The therapy expands eligibility to older and heavier patients, improving mobility and independence.
Source: www.arabianbusiness.com
